"Shares in the New Jersey-based company traded $0.27 higher at $18.69 in early trade yesterday on talk of a possible cash offer north of $40 a share. Roche, Merck and the UK’s AstraZeneca, 8p off at 4423.5p, were all tipped as being interested and each one could buy Insmed with loose change.
Bid speculation intensified this week when Insmed shares experienced unusually high volume in one hectic session. More than 650,000 shares changed hands against a normal daily average of 400,000. It led leaders to surmise that a predator could be stakebuilding before launching a knock-out bid."